论文部分内容阅读
目的:观察肺福康丸对慢性肺源性心脏病(肺心病)患者中医证候的影响.方法:将223例肺心病患者随机分为治疗组112例和对照组111例,两组均予以基础规范治疗,治疗组加服肺福康丸,分析患者治疗前与治疗l0d、30d后中医证候分布及演变情况.结果:治疗前,气虚、阴虚、痰凝、血瘀占全部证候信息的71.867％.治疗10d后治疗组气虚、血瘀、阴虚、痰凝占全部证候信息的68.845％;对照组气虚、血瘀、阴虚、痰凝占全部证候信息的78.604％.治疗30d后治疗组血瘀、气虚、痰凝、阴虚占全部证候信息的81.242％;对照组气虚、血瘀、痰凝、阴虚占全部证候信息的73.198％.结论:肺福康丸明显影响肺心病证候的演变.“,”Objective:To observe the TCM syndrome type and evolution of Cor Pulmonale with “Feifukang Wan”.Method:The 223 cases of pulmonary heart disease were randomly divided into 111 cases in treatment group and 112 cases in control group.Both groups were to be the basis of standard treatment.Treatment group took Feifukang Wan.Before and after 10 days,30 days treatment of syndrome type and evolution was compared.Results:The syndrome type before the treatment:Qi deficiency,deficiency of Yin,phlegm and water pathogens,stagnation of blood accounted for 71.867％ of all the syndrome type.The syndrome type after 10 days treatment:The treatment group:Qi deficiency,stagnation of blood,deficiency of Yin,phlegm and water pathogens accounted for 68.845％ of all the syndrome type;The control group:Qi deficiency,stagnation of blood、deficiency of Yin、phlegm and water pathogens accounted for 78.604％ of all the syndrome type.The syndrome type after 30 days treatment:The treatment group:stagnation of blood、Qi deficiency,phlegm and water pathogens、deficiency of Yin accounted for 81.242％ of all the syndrome type;The control group:Qi deficiency,stagnation of blood,phlegm and water pathogens,deficiency of Yin accounted for 73.198％ of all the syndrome type.Conclusion:“Feifukang Wan” can significantly affect the syndrome type of pulmonary heart disease.